- Details
- Sam Chang is joined by Patrick Soon-Shiong for a discussion on the effectiveness of N-803 for BCG unresponsive bladder cancer. They discussed the importance of an ideal profile for such an agent, which includes complete remission rate, durability of the response, and high cystectomy avoidance rate. They also highlighted the importance of the agent's safety and tolerability for urologists. The N-80...
|
- Details
- Vignesh Packiam joins Ashish Kamat to discuss a retrospective cohort study comparing the outcomes of patients with high-risk non-muscle-invasive bladder cancer (NMIBC) treated with either sequential intravesical gemcitabine and docetaxel or BCG therapy. The study included 312 patients treated at the University of Iowa tertiary care center. The primary outcome was high-grade recurrence-free surviva...
|
- Details
- Arnulf Stenzl joins Alicia Morgans to discuss the importance of proper and precise Transurethral Resection of Bladder Tumors (TURBT) as the first diagnostic step in bladder cancer treatment. He highlights the need for additional visualization techniques, such as photodynamic diagnosis or narrow-band imaging, to diagnose carcinoma in situ accurately. He also emphasizes the need to avoid piecemealin...
|
- Details
- Ashish Kamat is joined by Wei Shen Tan who presents highlights from the updated consensus on defining and managing intermediate-risk non-muscle-invasive bladder cancer (NMIBC). The intermediate-risk group is often a gray area, and there is some variation in different guidelines' definitions of intermediate-risk NMIBC. By standardizing the definition of intermediate-risk NMIBC, clinicians can bette...
|
- Details
- Wei Shen Tan joins Ashish Kamat to discuss the results of the HIVEC-II trial, a randomized controlled trial conducted across the UK that compares patients with adjuvant chemo hyperthermia with mitomycin to passive mitomycin at room temperature in the intermediate-risk non-muscle invasive bladder cancer. Adjuvant intravesical chemotherapy is the recommended standard of care for reducing the risk of...
|
- Details
- Andrea Necchi joins Alicia Morgans in a discussion on longer-term outcome data for non-muscle invasive bladder cancer patients without a carcinoma in-situ, cohort B in the KEYNOTE-057 study. The cohort B of the study focused on the patients without a CIS component and with only pTa or T1 papillary disease, high-risk disease, BCG-unresponsive disease. This is a difficult-to-treat patient population...
|
- Details
- Jeremy Teoh joins Ashish Kamat, providing a clinical perspective on recurrence mechanism of non-muscle invasive bladder cancer (NMIBC). The oncological control of NMIBC is often challenging, and the recurrence rates can be high. Dr. Teoh emphasizes the importance of understanding the mechanisms of recurrence, and in this discussion with Ashish Kamat highlights the following five mechanisms: undete...
|
- Details
- Neal Shore joins Alicia Morgans to discuss the benefits of Blue light cystoscopy (BLC) when patients receive this option for bladder cancer care in ambulatory surgery centers. BLC enhances urologists' ability to detect cancerous tissue, leading to more complete resection and reduced costs for the US healthcare system. Reimbursement for outpatient ambulatory surgery centers or clinics could be more...
|
- Details
- Kyle Rose joins Sam Chang in discussing his team's findings regarding the impact of cell-free urinary DNA on non-muscle invasive bladder cancer patients. This study aims to detect tumor alterations or mutations in the urine of high-risk non-invasive bladder cancer patients undergoing a repeat TURBT. Using whole exome sequencing and an ultra-deep sequencing platform, the study found that urinary tu...
|
- Details
- At the 2022 Large Urology Group Practice Association (LUGPA) annual CME meeting, Colin Dinney presented on the explosion of intravesical therapy for non-muscle invasive bladder cancer (NMIBC). Biography: Colin P. N. Dinney, MD, Chairman, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Related Content: EAU 2022: State-of-the-art Lectur...
|
